NASDAQ:TRVN

Trevena Competitors

$1.86
-0.39 (-17.33 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.64
Now: $1.86
$2.19
50-Day Range
$1.71
MA: $1.97
$2.25
52-Week Range
$0.61
Now: $1.86
$3.68
Volume13.68 million shs
Average Volume3.49 million shs
Market Capitalization$299.97 million
P/E RatioN/A
Dividend YieldN/A
Beta2.59

Competitors

Trevena (NASDAQ:TRVN) Vs. CDMO, PTGX, PHAT, MRSN, NKTX, and YMAB

Should you be buying TRVN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Trevena, including Avid Bioservices (CDMO), Protagonist Therapeutics (PTGX), Phathom Pharmaceuticals (PHAT), Mersana Therapeutics (MRSN), Nkarta (NKTX), and Y-mAbs Therapeutics (YMAB).

Trevena (NASDAQ:TRVN) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Trevena and Avid Bioservices, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trevena01302.75
Avid Bioservices00303.00

Trevena currently has a consensus target price of $5.00, indicating a potential upside of 168.82%. Avid Bioservices has a consensus target price of $17.3333, indicating a potential downside of 9.53%. Given Trevena's higher possible upside, equities analysts plainly believe Trevena is more favorable than Avid Bioservices.

Institutional & Insider Ownership

11.6% of Trevena shares are held by institutional investors. Comparatively, 58.2% of Avid Bioservices shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Comparatively, 1.7% of Avid Bioservices shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Trevena has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500.

Profitability

This table compares Trevena and Avid Bioservices' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrevenaN/A-42.49%-34.83%
Avid Bioservices0.20%0.31%0.13%

Earnings and Valuation

This table compares Trevena and Avid Bioservices' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$30,000.009,998.99$-24,870,000.00($0.27)-6.89
Avid Bioservices$59.70 million19.52$-10,470,000.00($0.27)-70.96

Avid Bioservices has higher revenue and earnings than Trevena. Avid Bioservices is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Summary

Avid Bioservices beats Trevena on 7 of the 12 factors compared between the two stocks.

Protagonist Therapeutics (NASDAQ:PTGX) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Protagonist Therapeutics and Trevena, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protagonist Therapeutics00703.00
Trevena01302.75

Protagonist Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 43.13%. Trevena has a consensus price target of $5.00, indicating a potential upside of 168.82%. Given Trevena's higher probable upside, analysts plainly believe Trevena is more favorable than Protagonist Therapeutics.

Institutional & Insider Ownership

97.5% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 11.6% of Trevena shares are owned by institutional investors. 14.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Protagonist Therapeutics has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Trevena has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500.

Profitability

This table compares Protagonist Therapeutics and Trevena's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protagonist Therapeutics-252.03%-54.00%-35.38%
TrevenaN/A-42.49%-34.83%

Valuation and Earnings

This table compares Protagonist Therapeutics and Trevena's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$230,000.005,056.97$-77,190,000.00($2.98)-8.91
Trevena$30,000.009,998.99$-24,870,000.00($0.27)-6.89

Trevena has lower revenue, but higher earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Summary

Trevena beats Protagonist Therapeutics on 9 of the 14 factors compared between the two stocks.

Phathom Pharmaceuticals (NASDAQ:PHAT) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Phathom Pharmaceuticals and Trevena, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Phathom Pharmaceuticals10402.60
Trevena01302.75

Phathom Pharmaceuticals presently has a consensus price target of $53.00, indicating a potential upside of 43.20%. Trevena has a consensus price target of $5.00, indicating a potential upside of 168.82%. Given Trevena's stronger consensus rating and higher probable upside, analysts plainly believe Trevena is more favorable than Phathom Pharmaceuticals.

Valuation and Earnings

This table compares Phathom Pharmaceuticals and Trevena's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.65
Trevena$30,000.009,998.99$-24,870,000.00($0.27)-6.89

Trevena has higher revenue and earnings than Phathom Pharmaceuticals. Trevena is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Phathom Pharmaceuticals and Trevena's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Phathom PharmaceuticalsN/A-88.73%-69.04%
TrevenaN/A-42.49%-34.83%

Institutional & Insider Ownership

73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.6% of Trevena shares are owned by institutional investors. 39.8% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Phathom Pharmaceuticals has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Trevena has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500.

Summary

Trevena beats Phathom Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Trevena (NASDAQ:TRVN) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Trevena and Mersana Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trevena01302.75
Mersana Therapeutics02502.71

Trevena currently has a consensus target price of $5.00, indicating a potential upside of 168.82%. Mersana Therapeutics has a consensus target price of $26.1667, indicating a potential upside of 57.16%. Given Trevena's stronger consensus rating and higher probable upside, analysts clearly believe Trevena is more favorable than Mersana Therapeutics.

Valuation & Earnings

This table compares Trevena and Mersana Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$30,000.009,998.99$-24,870,000.00($0.27)-6.89
Mersana Therapeutics$42.12 million27.29$-28,210,000.00($0.65)-25.62

Trevena has higher earnings, but lower revenue than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Trevena and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrevenaN/A-42.49%-34.83%
Mersana Therapeutics-8,772.91%-45.16%-37.53%

Institutional and Insider Ownership

11.6% of Trevena shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Comparatively, 5.3% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Trevena has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500.

Summary

Trevena beats Mersana Therapeutics on 11 of the 14 factors compared between the two stocks.

Trevena (NASDAQ:TRVN) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Trevena and Nkarta, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trevena01302.75
Nkarta00503.00

Trevena currently has a consensus target price of $5.00, indicating a potential upside of 168.82%. Nkarta has a consensus target price of $59.00, indicating a potential upside of 69.20%. Given Trevena's higher probable upside, analysts clearly believe Trevena is more favorable than Nkarta.

Valuation & Earnings

This table compares Trevena and Nkarta's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$30,000.009,998.99$-24,870,000.00($0.27)-6.89
NkartaN/AN/AN/AN/AN/A

Nkarta has lower revenue, but higher earnings than Trevena.

Profitability

This table compares Trevena and Nkarta's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrevenaN/A-42.49%-34.83%
NkartaN/AN/AN/A

Institutional and Insider Ownership

11.6% of Trevena shares are held by institutional investors. Comparatively, 77.1% of Nkarta shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Nkarta beats Trevena on 5 of the 8 factors compared between the two stocks.

Trevena (NASDAQ:TRVN) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Trevena and Y-mAbs Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trevena01302.75
Y-mAbs Therapeutics02602.75

Trevena currently has a consensus target price of $5.00, indicating a potential upside of 168.82%. Y-mAbs Therapeutics has a consensus target price of $58.1429, indicating a potential upside of 121.75%. Given Trevena's higher probable upside, analysts clearly believe Trevena is more favorable than Y-mAbs Therapeutics.

Valuation & Earnings

This table compares Trevena and Y-mAbs Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$30,000.009,998.99$-24,870,000.00($0.27)-6.89
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.40

Trevena has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Trevena and Y-mAbs Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TrevenaN/A-42.49%-34.83%
Y-mAbs TherapeuticsN/A-74.98%-66.70%

Institutional and Insider Ownership

11.6% of Trevena shares are held by institutional investors. Comparatively, 53.2% of Y-mAbs Therapeutics shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Comparatively, 38.4% of Y-mAbs Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Trevena has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Summary

Trevena beats Y-mAbs Therapeutics on 8 of the 11 factors compared between the two stocks.


Trevena Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43-1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51-6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41-2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.34-1.0%$950.61 millionN/A-12.60
Radius Health logo
RDUS
Radius Health
1.1$19.71-0.2%$924.28 million$173.32 million-8.08
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.45-0.5%$897.94 millionN/A0.00
Annexon logo
ANNX
Annexon
1.9$23.42-2.2%$893.66 millionN/A0.00Increase in Short Interest
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.95-0.1%$858.83 millionN/A-10.37Analyst Report
News Coverage
Merus logo
MRUS
Merus
1.6$22.52-1.7%$858.62 million$31.13 million-7.34Analyst Report
Ardelyx logo
ARDX
Ardelyx
1.6$8.69-0.3%$857.53 million$5.28 million-8.60High Trading Volume
Unusual Options Activity
News Coverage
Affimed logo
AFMD
Affimed
1.6$9.51-0.3%$839.98 million$23.96 million-16.12Earnings Announcement
News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$24.82-5.4%$838.42 millionN/A-22.98
Epizyme logo
EPZM
Epizyme
1.8$8.10-1.6%$824.46 million$23.80 million-3.63
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.30-0.3%$820.59 million$322.36 million123.57
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.27-0.8%$819.20 million$296.70 million47.49Analyst Revision
News Coverage
Humanigen logo
HGEN
Humanigen
1.7$14.73-5.6%$787.79 millionN/A0.00Increase in Short Interest
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.33-2.7%$782.70 millionN/A0.00Increase in Short Interest
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.02-0.1%$755.02 million$148.36 million-7.02Analyst Revision
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.05-3.2%$728.99 million$322.07 million-4.81Decrease in Short Interest
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.71-0.2%$728.84 million$40.89 million-3.35
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.63-1.9%$702.93 million$6.83 million-20.24
Chimerix logo
CMRX
Chimerix
1.3$8.18-1.6%$700.85 million$12.52 million-14.35Analyst Upgrade
Increase in Short Interest
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.71-7.0%$688.35 million$2.22 million-15.94
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.45-1.8%$680 million$13.80 million-14.23
Veru logo
VERU
Veru
1.4$9.42-1.8%$677.41 million$42.59 million-33.64Analyst Report
Analyst Revision
News Coverage
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$15.90-4.2%$673.79 million$17.26 million-4.42Analyst Revision
News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.92-0.5%$673.52 million$5.09 million-6.53Analyst Downgrade
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.88-1.2%$671.22 million$19.56 million-19.34
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28-1.3%$669.56 million$252 million-2.07High Trading Volume
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.